Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05480306 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of DKN-01 in Colorectal Cancer
A Phase 2 study, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
NCT05480306: Completed Phase 2 study, sponsored by Leap Therapeutics.
NCT05480306 is a Phase 2 study that has completed, run by Leap Therapeutics. The registered enrollment target is 188 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05480306, a Phase 2 study, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line treatment of advanced CRC patients.
Primary Outcome
PFS, as determined by the Investigator per RECIST v1.1 of DKN-01 plus SOC versus SOC.
Interventions
- DRUG Bevacizumab
- DRUG FOLFIRI
- DRUG FOLFOX
- DRUG DKN-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2025-07-10 |
| Phase | Phase 2 |
What the finished NCT05480306 record still lists
NCT05480306 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT05480306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05480306 about?
NCT05480306 is a clinical study titled "Phase 2 Study of DKN-01 in Colorectal Cancer". This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line treatment of advanced CRC patients.
What is the current status of trial NCT05480306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2022-08-30. Estimated completion is 2025-07-10.
What interventions are being tested in trial NCT05480306?
The interventions under investigation include: Bevacizumab (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG), DKN-01 (DRUG).
Who is sponsoring clinical trial NCT05480306?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05480306's enrollment target sits among peer trials
188 356th of 2000 higher than 1,644 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI